+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver And Kidney Disorders Drugs Market Research Reports

Membranous Nephropathy Drug Pipeline Analysis 2025 - Product Thumbnail Image

Membranous Nephropathy Drug Pipeline Analysis 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Liver Fibrosis Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Liver Fibrosis Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
IgA Nephropathy Pipeline Analysis 2025 - Product Thumbnail Image

IgA Nephropathy Pipeline Analysis 2025

  • Report
  • June 2025
  • 200 Pages
  • Global
From
Hepatitis B Virus (HBV) Infection Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Hepatitis B Virus (HBV) Infection Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
End Stage Renal Disease Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

End Stage Renal Disease Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Chronic Kidney Disease Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Chronic Kidney Disease Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Chronic Hepatitis B Virus Pipeline Analysis Report 2025 - Product Thumbnail Image

Chronic Hepatitis B Virus Pipeline Analysis Report 2025

  • Report
  • June 2025
  • 200 Pages
  • Global
From
Acute Pyelonephritis Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Acute Pyelonephritis Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
From
Chronic Hepatitis B Virus Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Chronic Hepatitis B Virus Epidemiology Forecast 2025-2034

  • Report
  • June 2025
  • 150 Pages
  • Global
From
Hepatitis D Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Hepatitis D Epidemiology Forecast 2025-2034

  • Report
  • June 2025
  • 150 Pages
  • Global
From
Calciphylaxis Market Report and Forecast 2025-2034 - Product Thumbnail Image

Calciphylaxis Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 400 Pages
  • Global
From
From
From
Kidney Stone Management Market Report and Forecast 2024-2032 - Product Thumbnail Image

Kidney Stone Management Market Report and Forecast 2024-2032

  • Report
  • August 2024
  • 200 Pages
  • Global
From
Chronic Kidney Disease (CKD) Drugs Market 2025-2029 - Product Thumbnail Image

Chronic Kidney Disease (CKD) Drugs Market 2025-2029

  • Report
  • June 2025
  • 228 Pages
  • Global
From
Non-alcoholic Steatohepatitis (NASH) Market 2024-2028 - Product Thumbnail Image

Non-alcoholic Steatohepatitis (NASH) Market 2024-2028

  • Report
  • August 2024
  • 154 Pages
  • Global
From
Hyperkalemia Drugs Market 2024-2028 - Product Thumbnail Image

Hyperkalemia Drugs Market 2024-2028

  • Report
  • August 2024
  • 139 Pages
  • Global
From
Milk Thistle Products Market 2024-2028 - Product Thumbnail Image

Milk Thistle Products Market 2024-2028

  • Report
  • August 2024
  • 141 Pages
  • Global
From
From
Loading Indicator

The Liver and Kidney Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs to treat diseases and disorders of the liver and kidneys. These drugs are used to treat a variety of conditions, including hepatitis, cirrhosis, kidney failure, and other kidney-related diseases. The market is highly competitive, with many companies vying for market share. The market is driven by the increasing prevalence of liver and kidney diseases, as well as the development of new treatments and technologies. Additionally, the rising demand for better treatments and the increasing availability of generic drugs are also contributing to the growth of the market. Some of the major companies in the Liver and Kidney Disorders Drugs market include Pfizer, Merck, Novartis, Sanofi, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and AbbVie. These companies are engaged in the development and production of drugs to treat liver and kidney diseases. Show Less Read more